Comparison between Akme Fintrade IPO and Emcure Pharmaceuticals IPO.
Akme Fintrade IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Emcure Pharmaceuticals IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Akme Fintrade IPO is up to ₹132.00 Cr whereas the issue size of the Emcure Pharmaceuticals IPO is up to ₹1,952.03 Cr. The final issue price of Akme Fintrade IPO is ₹120.00 per share and of Emcure Pharmaceuticals IPO is ₹1,008.00 per share.
| Akme Fintrade IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹114.00 per share | ₹960.00 per share |
| Issue Price (Upper) | ₹120.00 per share | ₹1,008.00 per share |
| Issue Price (Final) | ₹120.00 per share | ₹1,008.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | ₹90.00 per share |
| Market Lot Size | 125 shares | 14 shares |
| Fresh Issue Size | 1,10,00,000 shares | 79,46,231 shares |
| Fresh Issue Size (Amount) | up to ₹132.00 Cr | up to ₹800.58 Cr |
| OFS Issue Size | 0 shares | 1,14,28,839 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹1,151.45 Cr |
| Issue Size Total | 1,10,00,000 shares | 1,93,75,070 shares |
| Issue Size Total (Amount) | up to ₹132.00 Cr | up to ₹1,952.03 Cr |
Akme Fintrade IPO opens on Jun 19, 2024, while Emcure Pharmaceuticals IPO opens on Jul 03, 2024. The closing date of Akme Fintrade IPO and Emcure Pharmaceuticals IPO is Jun 21, 2024, and Jul 05, 2024, respectively.
| Akme Fintrade IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Jun 18, 2024 | Jul 02, 2024 |
| Issue Open | Jun 19, 2024 | Jul 03, 2024 |
| Issue Close | Jun 21, 2024 | Jul 05, 2024 |
| Basis Of Allotment (Tentative) | Jun 24, 2024 | Jul 08, 2024 |
| Initiation of Refunds (Tentative) | Jun 25, 2024 | Jul 09, 2024 |
| Credit of Share (Tentative) | Jun 25, 2024 | Jul 09, 2024 |
| Listing date (Tentative) | Jun 26, 2024 | Jul 10, 2024 |
| Anchor Lockin End date 1 | Jul 24, 2024 | Aug 07, 2024 |
| Anchor Lockin End date 2 | Sep 22, 2024 | Oct 06, 2024 |
Akme Fintrade IPO P/E ratio is , as compared to Emcure Pharmaceuticals IPO P/E ratio of 34.55.
| Akme Fintrade IPO | Emcure Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 56.01 | 83.21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 78.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 34.55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹19029.89 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 5.64% | 16.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 19.37% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.49 | 0.67 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹3.87 | ₹29.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 5.81% | 16.87% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Akme Fintrade IPO Retail Individual Investors (RII) are offered 36,57,500 shares while in Emcure Pharmaceuticals IPO retail investors are offered 36,57,500 shares. Qualified Institutional Buyers (QIB) are offered 20,90,000 shares in Akme Fintrade IPO and 38,53,234 shares in Emcure Pharmaceuticals IPO.
| Akme Fintrade IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 31,35,000 shares | 57,79,850 shares |
| Market Maker Reservation | ||
| QIB | 20,90,000 shares | 38,53,234 shares |
| NII | 15,67,500 shares | 28,89,926 shares |
| RII | 36,57,500 shares | 67,43,160 shares |
| Employee | 5,50,000 shares | 1,08,900 shares |
| Others | ||
| Total | 1,10,00,000 shares | 1,93,75,070 shares |
Akme Fintrade IPO subscribed 54.49x in total, whereas Emcure Pharmaceuticals IPO subscribed 67.87x.
| Akme Fintrade IPO | Emcure Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 28.12x | 191.24x |
| NII (times) | 129.98x | 49.32x |
| Big NII (times) | 121.56x | 54.90x |
| Small NII (times) | 146.83x | 38.16x |
| RII (times) | 44.58x | 7.36x |
| Employee (times) | 5.42x | 8.81x |
| Other (times) | ||
| Total (times) | 54.49x | 67.87x |
